A Gene Expression Profile Test for the Differential Diagnosis of Ovarian Versus Endometrial Cancers

Anita Lal; Rebecca Panos; Mira Marjanovic; Michael Walker; Eloisa Fuentes; Daniel S. Kapp; W David Henner; Ljubomir J. Buturovic; Meredith Halks-Miller

doi:10.18632/oncotarget.450

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Methodological Reports:

A Gene Expression Profile Test for the Differential Diagnosis of Ovarian Versus Endometrial Cancers

Anita Lal _, Rebecca Panos, Mira Marjanovic, Michael Walker, Eloisa Fuentes, Daniel S. Kapp, W David Henner, Ljubomir J. Buturovic and Meredith Halks-Miller

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2012; 3:212-223. https://doi.org/10.18632/oncotarget.450

Metrics: PDF 2187 views | HTML 2771 views | ?

Abstract

Anita Lal¹, Rebecca Panos¹, Mira Marjanovic¹, Michael Walker¹, Eloisa Fuentes¹, Daniel S Kapp², W. David Henner¹, Ljubomir J. Buturovic¹ and Meredith Halks-Miller¹

¹ Pathwork Diagnostics, Redwood City, CA-94063

² Department of Radiation Oncology, Stanford University, Stanford, CA-94305

Received: January 15, 2012; Accepted: February 21, 2012; Published: February 23, 2012;

Keywords: gene expression, tissue of origin, endometrial cancer, ovarian cancer, diagnostic test

Correspondence:

Anita Lal,

Abstract

We have developed a gene expression profile test (Pathwork Tissue of Origin Endometrial Test) that distinguishes primary epithelial ovarian and endometrial cancers in formalin-fixed, paraffin-embedded (FFPE) specimens using a 316–gene classification model. The test was validated in a blinded study using a pre-specified algorithm and microarray files for 75 metastatic, poorly differentiated or undifferentiated specimens with a known ovarian or endometrial cancer diagnosis. Measures of test performance include a 94.7% overall agreement with the known diagnosis, an area under the ROC curve (AUC) of 0.997 and a diagnostic odds ratio (DOR) of 406. Ovarian cancers (n=30) gave an agreement of 96.7% with the known diagnosis while endometrial cancers (n=45) gave an agreement of 93.3%. In a precision study, concordance in test results was 100%. Reproducibility in test results between three laboratories was 94.3%. The Tissue of Origin Endometrial Test can aid in resolving important differential diagnostic questions in gynecologic oncology.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 450

Publication Alerts

Methodological Reports:

A Gene Expression Profile Test for the Differential Diagnosis of Ovarian Versus Endometrial Cancers

Abstract